Endo's combination with Mallinckrodt granted ruling from Irish High Court
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 17 2025
0mins
Should l Buy ?
Merger Approval: Endo and Mallinckrodt have received a ruling from the Irish High Court that allows their planned merger to proceed, following shareholder approval.
Future Plans: The combined company will be headquartered in Dublin and intends to merge their generic pharmaceuticals and sterile injectables businesses, with plans for future separation subject to Board approval.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
